Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community

Circulation

Volumn 119, Issue 12, 2009, Pages 1592-1600

  Böger, Rainer H ^a   Sullivan, Lisa M ^b,c   Schwedhelm, Edzard ^a   Wang, Thomas J ^b,d   Maas, Renke ^a   Benjamin, Emelia J ^b,c   Schulze, Friedrich ^a   Xanthakis, Vanessa ^b,c   Benndorf, Ralf A ^a   Vasan, Ramachandran S ^a,b,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b FRAMINGHAM HEART STUDY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cardiovascular diseases; Epidemiology; Nitric oxide; Population; Risk factors

Indexed keywords

ALBUMIN; ARGININE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; RENIN; DRUG DERIVATIVE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE;

ADULT; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; COMMUNITY SAMPLE; DIABETES MELLITUS; DISEASE COURSE; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; INCIDENCE; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLASMA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK; URINARY EXCRETION; AGED; BLOOD; CAUSE OF DEATH; MIDDLE AGED; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL;

AGED; ARGININE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 65249119330     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.838268     Document Type: Article

References (41)

1. Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide. 2001;5:88-97.
2. Palmer RM, Rees DD, Ashton DS, Moncada S. L-Arginine is the physiological precursor for the formation of nitric oxide in endothelium- dependent relaxation. Biochem Biophys Res Commun. 1988;153: 1251-1256.
3. Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003;59:824-833.
4. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
5. Krempl TK, Maas R, Sydow K, Meinertz T, Boger RH, Kahler J. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J. 2005;26: 1846-1851.
6. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 2003;24:1912-1919.
7. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Munzel T. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res. 2005;97:e53-e59.
8. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358: 2113-2117.
9. Boger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med. 2006;38:126-136.
10. Maas R, Schulze F, Baumert J, Lowel H, Hamraz K, Schwedhelm E, Koenig W, Boger RH. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem. 2007;53:693-701.
11. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358:2127-21278.
12. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-2639.
13. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 1979;110:281-290.
14. Kannel WB, Wolf PA, Garrison RJ, eds. Section 34: Some Risk Factors Related to the Annual Incidence of Cardiovascular Disease and Death in Pooled Repeated Biennial Measurements: Framingham Heart Study, 30 Year Follow-Up. Bethesda, Md: US Department of Health and Human Services; 1987.
15. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Boger RH. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem. 2005;51:1268-1271.
16. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, Boger RH. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:211-219.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creat- inine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
18. Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc. 1972;34(series B):187-220.
19. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-Boger SM. LDL cholesterol upregulates synthesis of asymmetrical dim- ethylarginine in human endothelial cells: involvement of S-adenosylmethionine- dependent methyltransferases. Circ Res. 2000;87:99-105.
20. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842-1847.
21. Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, Berka V, Zweier JL. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem. 2007;282:879-887.
22. Ardigo D, Stuehlinger M, Franzini L, Valtuena S, Piatti PM, Pachinger O, Reaven GM, Zavaroni I. ADMA is independently related to flow- mediated vasodilation in subjects at low cardiovascular risk. Eur J Clin Invest. 2007;37:263-269.
23. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899-1906.
24. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethyl- arginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003; 23:1455-1459.
25. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, Hoeper MM, Haller H, Fliser D. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation. 2004;109:172-177.
26. Nicholls SJ, Wang Z, Koeth R, Levison B, DelFraino B, Dzavik V, Griffith OW, Hathaway D, Panza JA, Nissen SE, Hochman JS, Hazen SL. Metabolic profiling of arginine and nitric oxide pathways predicts hemo- dynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction. Circulation. 2007;116:2315-2324.
27. O'Dwyer MJ, Dempsey F, Crowley V, Kelleher DP, McManus R, Ryan T. Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study. Crit Care. 2006;10:R139.
28. Nakata S, Tsutsui M, Shimokawa H, Suda O, Morishita T, Shibata K, Yatera Y, Sabanai K, Tanimoto A, Nagasaki M, Tasaki H, Sasaguri Y, Nakashima Y, Otsuji Y, Yanagihara N. Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation. 2008;117:2211-2223.
29. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, Marz W. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem. 2007;53:273-283.
30. Leong T, Zylberstein D, Graham I, Lissner L, Ward D, Fogarty J, Bengtsson C, Bjorkelund C, Thelle D. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the Population Study of Women in Gothenburg. Arterioscler Thromb Vasc Biol. 2008;28:961-967.
31. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY, Tsao PS, Kimoto M, Vallance P, Patterson AJ, Cooke JP. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation. 2003;108:3042-3047.
32. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O'Hara B, Rossiter S, Anthony S, Madhani M, Selwood D, Smith C, Wojciak- Stothard B, Rudiger A, Stidwill R, McDonald NQ, Vallance P. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med. 2007;13:198-203.
33. Mittermayer F, Krzyzanowska K, Exner M, Mlekusch W, Amighi J, Sabeti S, Minar E, Muller M, Wolzt M, Schillinger M. Asymmetric dimethyl- arginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol. 2006;26:2536-2540.
34. Maas R, Dentz L, Schwedhelm E, Thorns W, Kuss O, Hiltmeyer N, Haddad M, Kloss T, Standl T, Boger RH. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethyl- arginine predict adverse events in patients undergoing noncardiac surgery. Crit Care Med. 2007;35:1876-1881.
35. Paiva H, Lehtimaki T, Laakso J, Ruokonen I, Rantalaiho V, Wirta O, Pasternack A, Laaksonen R. Plasma concentrations of asymmetric- dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism. 2003;52:303-307.
36. Krzyzanowska K, Mittermayer F, Shnawa N, Hofer M, Schnabler J, Etmuller Y, Kapiotis S, Wolzt M, Schernthaner G. Asymmetrical dim- ethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with type 2 diabetes and albuminuria. Diabet Med. 2007;24:81-86.
37. Schwedhelm E. Quantification of ADMA: analytical approaches. Vasc Med. 2005;10(suppl 1):S89-S95.
38. Pritchard KA Jr, Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, Wolin MS, Stemerman MB. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res. 1995;77:510-518.
39. Forstermann U. Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol Chem. 2006;387:1521-1533.
40. Dixon LJ, Hughes SM, Rooney K, Madden A, Devine A, Leahey W, Henry W, Johnston GD, McVeigh GE. Increased superoxide production in hypertensive patients with diabetes mellitus: role of nitric oxide synthase. Am J Hypertens. 2005;18:839-843.
41. Jay D, Hitomi H, Griendling KK. Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med. 2006;40:183-192.